Eli Lilly and Company (NYSE:LLY) received a modest price target raise on September 18 from Guggenheim. The brokerage increased its target to $1,284 from $1,273 while maintaining a Buy rating on the ph
Eli Lilly's share price climb has decelerated in 2026.
Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) were once viewed as the two big winners of the GLP-1 boom. However, the market’s view of the two companies has changed sharply. Since m
Eli Lilly (NYSE:LLY) received FDA approval for Olumiant to treat pediatric patients with severe alopecia areata. The FDA also cleared once weekly insulin Onswik for adults with type 2 diabetes, adding
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved Olumiant (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years
Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the
View interactive chart, options flow, and AI analysis for LLY on Zorveq Finance.
Open LLY Chart & Analysis →